Iloperidone
- Generic Name
- Iloperidone
- Brand Names
- Fanapt
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27FN2O4
- CAS Number
- 133454-47-4
- Unique Ingredient Identifier
- VPO7KJ050N
- Background
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals ga...
- Indication
Treatment of acute schizophrenia.
- Associated Conditions
- Schizophrenia
- Associated Therapies
- -
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05648591
- Locations
- 🇺🇸
Vanda Investigational Site, Everett, Washington, United States
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Vanda Pharmaceuticals
- Registration Number
- NCT05344365
- Locations
- 🇺🇸
Vanda Investigational Site, Saint Petersburg, Florida, United States
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 417
- Registration Number
- NCT04819776
- Locations
- 🇵🇱
Vanda Investigational Site, Tuszyn, Poland
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT04712734
- Locations
- 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT04127058
- Locations
- 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT02453893
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Iloperidone in Mixed States of Bipolar Disorder
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2018-02-08
- Target Recruit Count
- 41
- Registration Number
- NCT02413918
- Locations
- 🇺🇸
UT Health Science Center San Antonio, San Antonio, Texas, United States
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 19
- Registration Number
- NCT01929889
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01920802
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.